Cost‐effectiveness of solvent/detergent‐treated fresh‐frozen plasma

Background and Objectives Although transfusion‐transmitted infections are rare, non‐infectious complications occur relatively frequently. Solvent/detergent‐treated fresh‐frozen plasma (SD‐FFP) has been shown to reduce the frequency of both types of complication, although previous economic evaluations failed to consider non‐infective events and subsequently underestimated the benefits of SD‐FFP.

[1]  S. Moore,et al.  Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. , 2015, The American review of respiratory disease.

[2]  G. Opelz,et al.  Kidney graft failure and presensitization against HLA Class I and Class II antigens1 , 2002, Transplantation.

[3]  E. Vamvakas.  Long‐term survival of transfusion recipients in Sweden, 1993 , 2001, Transfusion.

[4]  M. Popovsky.  Transfusion and lung injury. , 2001, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[5]  Arturo Pereira,et al.  Health and economic consequences of HCV lookback , 2001, Transfusion.

[6]  T. Erb,et al.  Solvent-detergent-treated fresh frozen plasma: a superior alternative to standard fresh frozen plasma? , 2000, Journal of cardiothoracic and vascular anesthesia.

[7]  S. Kleinman,et al.  The risks of transfusion-transmitted infection: direct estimation and mathematical modelling. , 2000, Bailliere's best practice & research. Clinical haematology.

[8]  J. Allain,et al.  Emerging viral infections relevant to transfusion medicine. , 2000, Blood reviews.

[9]  Arturo Pereira,et al.  A model of the health and economic impact of posttransfusion hepatitis C: application to cost‐effectiveness analysis of further expansion of HCV screening protocols , 2000, Transfusion.

[10]  L. Markson,et al.  Costs of care for HIV infection in a managed care population from 1995 to 1997. , 2000, The American journal of managed care.

[11]  P. Marcellin,et al.  Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases. , 2000, Journal of hepatology.

[12]  M. Sivakumaran.  Universal leucodepletion to reduce the risk of transmission of new‐variant creutzfeldt–jakob disease , 2000, British journal of haematology.

[13]  E. Vamvakas.  The cost‐effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion , 2000, Transfusion.

[14]  J. Birkmeyer,et al.  Update of cost-effectiveness analysis for solvent-detergent-treated plasma. , 1999, Journal of the American Medical Association (JAMA).

[15]  A. Pereira.  Cost‐effectiveness of transfusing virus‐inactivatedplasma instead of standard plasma , 1999, Transfusion.

[16]  M. Collins,et al.  Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: review of database , 1999, BMJ.

[17]  B. Kubanek,et al.  Estimated Risk of Transmission of Hepatitis C Virus by Blood Transfusion , 1998, Vox Sanguinis.

[18]  S. Holme.  Storage and Quality Assessment of Platelets , 1998, Vox sanguinis.

[19]  B. Horowitz,et al.  Virus Inactivation by Solvent/Detergent Treatment and the Manufacture of SD‐Plasma , 1998, Vox sanguinis.

[20]  L. Biesert,et al.  Solvent/Detergent Treatment of Human Plasma ‐ A Very Robust Method for Virus Inactivation. Validated Virus Safety of OCTAPLAS® , 1998, Vox sanguinis.

[21]  A. Coenen,et al.  Hemovigilance: Clinical Tolerance of Solvent‐Detergent Treated Plasma , 1998, Vox sanguinis.

[22]  H. Rollag,et al.  Viral Safety of Blood Derivatives by Immune Neutralization , 1998, Vox sanguinis.

[23]  C. Bradbeer,et al.  ABC of palliative care: HIV infection and AIDS , 1997 .

[24]  A. Paterson,et al.  The association of biologically active lipids with the development of transfusion‐related acute lung injury: a retrospective study , 1997, Transfusion.

[25]  E. Vamvakas,et al.  Length of survival after perioperative transfusion , 1997, Transfusion medicine.

[26]  S. Kleinman,et al.  The Risk of Transfusion-Transmitted Viral Infections , 1996 .

[27]  F. Becker,et al.  Transfusion‐related acute lung injury due to HLA‐A2‐specific antibodies in recipient and NB1‐specific antibodies in donor blood , 1996, British journal of haematology.

[28]  Jennifer A. Roberts,et al.  Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal , 1995, Hepatology.

[29]  Joseph G. Weber,et al.  What is the incidence of perioperative transfusion-related acute lung injury? , 1995, Anesthesiology.

[30]  J. Birkmeyer,et al.  Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. , 1994, JAMA.

[31]  E. Schiff,et al.  Transfusion transmission of retroviruses: human T‐lymphotropic virus types I and II compared with human immunodeficiency virus type 1 , 1994, Transfusion.

[32]  E. Vamvakas,et al.  Long‐term survival after blood transfusion , 1994, Transfusion.

[33]  D. S. Sherlock.  Treatment of chronic hepatitis , 1994 .

[34]  J. Birkmeyer,et al.  The cost‐effectiveness of preoperative autologous blood donation for total hip and knee replacement , 1993, Transfusion.

[35]  S. Moore,et al.  Transfusion‐related acute lung injury: a neglected, serious complication of hemotherapy , 1992, Transfusion.

[36]  G. Whyte,et al.  The Transfused Population of Canterbury, New Zealand, and Its Mortality , 1988, Vox sanguinis.

[37]  S. Moore,et al.  Diagnostic and pathogenetic considerations in transfusion‐related acute lung injury , 1985, Transfusion.

[38]  D. Quinton,et al.  Unit Costs of Health and Social Care 2004 , 2004 .

[39]  農林水産奨励会農林水産政策情報センター,et al.  The green book : appraisal and evaluation in central government , 2003 .

[40]  E. Vamvakas.  Risk of transmission of Creutzfeldt‐Jakob disease by transfusion of blood, plasma, and plasma derivatives , 1999, Journal of clinical apheresis.

[41]  S. Kleinman,et al.  The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. , 1996, The New England journal of medicine.

[42]  G. Sloop,et al.  Complications of blood transfusion. How to recognize and respond to noninfectious reactions. , 1995, Postgraduate medicine.

[43]  J. Birkmeyer,et al.  Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. , 1994, The Annals of thoracic surgery.

[44]  P I Terasaki,et al.  Long-term survival. , 1988, Clinical transplants.